E

Evotec SE
OTC:EVOTF

Watchlist Manager
Evotec SE
OTC:EVOTF
Watchlist
Price: 8.01 USD Market Closed
Market Cap: $1.4B

Net Margin

-21%
Current
Declining
by 2.7%
vs 3-y average of -18.4%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-21%
=
Net Income
€-159m
/
Revenue
€756.3m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-21%
=
Net Income
$-159m
/
Revenue
€756.3m

Peer Comparison

Country Company Market Cap Net
Margin
DE
Evotec SE
XETRA:EVT
1.1B EUR
Loading...
US
PerkinElmer Inc
LSE:0KHE
1.2T USD
Loading...
US
Thermo Fisher Scientific Inc
NYSE:TMO
223.2B USD
Loading...
US
Danaher Corp
NYSE:DHR
154.9B USD
Loading...
KR
Samsung Biologics Co Ltd
KRX:207940
82.4T KRW
Loading...
CH
Lonza Group AG
SIX:LONN
37.3B CHF
Loading...
US
IQVIA Holdings Inc
NYSE:IQV
40.3B USD
Loading...
CN
WuXi AppTec Co Ltd
SSE:603259
274.9B CNY
Loading...
US
Agilent Technologies Inc
NYSE:A
37.4B USD
Loading...
US
Mettler-Toledo International Inc
NYSE:MTD
28.2B USD
Loading...
FR
Sartorius Stedim Biotech SA
PAR:DIM
18.6B EUR
Loading...

Market Distribution

Lower than 86% of companies in Germany
Percentile
14th
Based on 3 835 companies
14th percentile
-21%
Low
-222 027.4% — -2%
Typical Range
-2% — 6%
High
6% — 85 055.6%
Distribution Statistics
Germany
Min -222 027.4%
30th Percentile -2%
Median 2.2%
70th Percentile 6%
Max 85 055.6%

Evotec SE
Glance View

Nestled within Germany's innovation-focused sector, Evotec SE has carved a niche for itself as a leading player in the field of drug discovery and development solutions. From its inception, Evotec has thrived on its commitment to delivering comprehensive solutions that expedite the journey from conceptualization to clinical success. At the core of its business model is a robust and scalable platform approach, which integrates cutting-edge technologies such as high-throughput screening, phenotypic screening, and computational biology. By leveraging these advanced methodologies, Evotec collaborates with pharmaceutical giants, biotech firms, and academic institutions, offering them customized services and shared-risk alliances. This symbiotic partnership model not only accelerates drug discovery but also minimizes the resource constraints typically associated with early-stage research. Evotec's revenue generation is intricately tied to its partnerships and collaborations, which involve milestone and royalty payments, alongside direct service fees. Its business strategy is propelled by a unique combination of proprietary drug development initiatives and strategic collaborative ventures. This dual-pronged approach allows Evotec to share the financial risk of drug development while maintaining potential upside through successful compounds. Moreover, the company's proactive investments in its own pipeline complement the service-based revenue, as they position Evotec to capture significant gains from future licensing or the eventual commercialization of internally researched drugs. With a strong emphasis on scientific excellence and commercial viability, Evotec meticulously balances innovation with strategic foresight, crafting a sustainable business that stands resilient amid the ever-evolving pharmaceutical landscape.

EVOTF Intrinsic Value
10.85 USD
Undervaluation 26%
Intrinsic Value
Price
E
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-21%
=
Net Income
€-159m
/
Revenue
€756.3m
What is Evotec SE's current Net Margin?

The current Net Margin for Evotec SE is -21%, which is below its 3-year median of -18.4%.

How has Net Margin changed over time?

Over the last 3 years, Evotec SE’s Net Margin has increased from -25.8% to -21%. During this period, it reached a low of -26.3% on Mar 31, 2025 and a high of -10.7% on Dec 31, 2023.

Back to Top